05/14/2018

Recent Oncology Related Drug News

LONSURF Pivotal Phase 3 Trial Results

The pivotal Phase 3 (TAGS) trial evaluating LONSURF® (trifluridine and tipiracil) plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer, met its primary endpoint of prolonged overall survival (OS). 
 
Please find our announcement press release offering additional details. CLICK HERE

 FDA approval of Akynzeo IV

Helsinn Therapeutics, (U.S.), Inc. would like to announce that AKYNZEO® (fosnetupitant and palonosetron) for injection on April 19, 2018 was approved by the U.S. Food and Drug Administration.

AKYNZEO for injection should be billed using:

miscellaneous HCPCS J code—J3490, (unclassified, drug)

235mg fosnetupitant/0.25 mg palonosetron in single-dose vial =1 billing unit and NDC# 69639-0102-01

Check with your Payers for specific billing requirements for AKYNZEO for injection.

Helsinn Cares™ is committed to providing healthcare professionals, patients, and caregivers with the resources and information needed for access and reimbursement support.

For answers to specific questions on Helsinn Cares (www.helsinnreimbursement.com) or please call 1-84HELSINN-U (1-844-357-4668, select prompt 2) or fax: 1-844-357-4669.

For medical information, please call: 1-855-541-3495. For AKYNZEO for injection, please see the full Prescribing Information.